Recent 8-K filings for TWST

• May 4, 2026, 7:59 PM ET earnings materiality 0.80 positive item 2.02item 9.01 ◈ Earnings Releases

  Twist Bioscience Q2 revenue $110.7M (+19% YoY); raises FY2026 revenue guidance to $442-447M

  Record revenue $110.7M, 13th consecutive quarter of sequential growth; gross margin 51.6% (+2 pts YoY).

• February 17, 2026, 6:59 PM ET M&A materiality 0.70 neutral item 3.02item 8.01item 9.01

  Twist Bioscience to issue up to 632,328 shares for Invenra license and equity stake

  Total consideration: up to 632,328 TWST shares plus $5M cash.

• February 6, 2026, 6:59 PM ET other materiality 0.10 neutral item 5.07

  Twist Bioscience stockholders elect three directors, approve say-on-pay and auditor ratification at 2026 annual meeting

  Keith Crandell, Jan Johannessen, and Trynka Shineman Blake elected as Class II directors with over 40M votes for each.

• February 2, 2026, 6:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  Twist Bioscience Q1 FY26: Record revenue $103.7M (+17% YoY), raises FY guidance to $435-440M

  Revenue $103.7M (+17% YoY), 12th consecutive sequential growth; exceeded guidance.

• January 12, 2026, 6:59 PM ET earnings materiality 0.70 positive item 2.02item 9.01

  Twist Bioscience preliminary Q1 FY2026 revenue ~$103.7M, up 17% YoY, ahead of guidance

  Preliminary Q1 FY2026 revenue ~$103.7M (+/- $0.2M), 17% YoY growth, above guidance of $100-101M.

• November 14, 2025, 6:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  Twist Bioscience FY2025 revenue $376.6M (+20% YoY); guides for adjusted EBITDA breakeven in Q4 FY2026

  Record FY2025 revenue $376.6M (+20% YoY); Q4 revenue $99.0M (+17% YoY), 11th consecutive sequential growth.

• August 6, 2025, 7:59 PM ET leadership materiality 0.50 positive item 5.02item 9.01

  Twist Bioscience appoints Trynka Shineman Blake to Board of Directors

  Trynka Shineman Blake elected to Twist board and appointed to Audit Committee, effective August 5, 2025.

• August 4, 2025, 7:59 PM ET earnings materiality 0.85 positive item 2.02item 9.01

  Twist Bioscience reports record Q3 revenue $96.1M (+18% YoY); swings to GAAP net income $20.4M

  Record revenue $96.1M, up 18% YoY; NGS revenue grew 27% to $55.3M.

• May 5, 2025, 7:59 PM ET other material materiality 0.90 positive item 1.01item 2.02item 7.01item 9.01

  Twist reports record Q2 revenue $92.8M; spins out DNA data storage as Atlas with $155M investment

  Record Q2 revenue $92.8M (+23% YoY); gross margin 49.6% vs 41.0%.

• February 11, 2025, 6:59 PM ET other material materiality 0.55 neutral item 5.02item 5.07item 5.03item 9.01

  Twist Bioscience shareholders approve 100M share increase, equity plan amendment

  Shareholders approved increase in authorized common stock by 100,000,000 shares (Proposal Five).

• February 3, 2025, 6:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  Twist Bioscience Q1 FY2025 revenue $88.7M (+24% YoY), gross margin 48.3%, net loss narrows to $31.6M

  Total revenue $88.7M vs $71.5M YoY; SynBio +28% to $34.4M, NGS +23% to $48.6M.

• November 18, 2024, 6:59 PM ET earnings materiality 0.70 positive item 2.02item 9.01

  Twist Bioscience FY2024 rev $313.0M (+28% YoY); Q4 gross margin 45.1%; FY2025 rev guidance $367M-$377M

  FY2024 revenue $313.0M, up 28% vs FY2023; Q4FY24 revenue $84.7M, up 27% YoY, 7th consecutive sequential growth.

• October 15, 2024, 7:59 PM ET leadership materiality 0.30 neutral item 5.02

  Twist Bioscience enters month-to-month consulting agreement with James Thorburn at $25K/mo

  James Thorburn's previous employment agreement as Strategic Advisor expired; new consulting deal effective October 8, 2024.

• August 2, 2024, 7:59 PM ET earnings materiality 0.80 positive item 2.02item 9.01

  Twist Bioscience Q3 FY2024 revenue $81.5M (+28% YoY); raises FY2024 guidance to ~$310-311M

  Revenue $81.5M, up 28% YoY; gross margin 43.3%, up ~900 bps from 34.4%.

• May 2, 2024, 7:59 PM ET earnings materiality 0.85 positive item 2.02item 9.01 ◈ Earnings Releases ×2

  Twist Bioscience reports record Q2 revenue $75.3M (+25% YoY), raises FY2024 guidance

  Record revenue $75.3M (+25% YoY); orders $93.2M (+45% YoY).

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.90 · Median 0.75 · Most common event earnings

11 positive 0 negative 4 neutral

source · TWST on sec.gov